Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20030032.TNBC

— · D

6ed214df-298a-5b3b-ac78-1f302810d233

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
  • ANGIOGENESIS+0.400
  • MYOGENESIS+0.390
  • HEDGEHOG_SIGNALING+0.380
  • WNT_BETA_CATENIN_SIGNALING+0.380
  • APICAL_JUNCTION+0.360
  • INTERFERON_ALPHA_RESPONSE+0.300
  • INTERFERON_GAMMA_RESPONSE+0.290
  • MITOTIC_SPINDLE+0.280
  • NOTCH_SIGNALING+0.280

Top 10 suppressed

  • MYC_TARGETS_V1-0.500
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • PROTEIN_SECRETION-0.490
  • ANDROGEN_RESPONSE-0.400
  • ADIPOGENESIS-0.390
  • MTORC1_SIGNALING-0.380
  • FATTY_ACID_METABOLISM-0.320
  • ESTROGEN_RESPONSE_LATE-0.290
  • ESTROGEN_RESPONSE_EARLY-0.280
  • UNFOLDED_PROTEIN_RESPONSE-0.270

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120020022.TNBC
breast-umap@18
—D0.887
2MBCProject_0582_T1_RNA
breast-umap@18
—D0.865
3SRR23303731
bladder-landscape@3
——0.846
4SRR8518330
breast-umap@18
—D0.844
5TCGA-C8-A8HR-01A-11R-A36F-07
breast-umap@18
—A0.837
6BSR_12_0175_A5_S64
breast-umap@18
—D0.831
7DRR168520
bladder-landscape@3
——0.817
8SRR10900585
melanoma-umap@29
——0.816
9SRR35579837
breast-umap@18
—D0.813
10SRR8613770
breast-umap@18
—E0.810

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.540Inavolisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
MYOGENESIS0.390Inavolisib— uncovered
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.380Inavolisib— uncovered
APICAL_JUNCTION0.360Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.290Idelalisib— uncovered
MITOTIC_SPINDLE0.280Inavolisib— uncovered
NOTCH_SIGNALING0.280Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.250Inavolisib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
APICAL_SURFACE0.180Temsirolimus— uncovered
ALLOGRAFT_REJECTION0.170Idelalisib— uncovered
COAGULATION0.160Binimetinib— uncovered
HYPOXIA0.150Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.150Idelalisib— uncovered
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered
COMPLEMENT0.110Inavolisib— uncovered
G2M_CHECKPOINT0.110Inavolisib— uncovered